http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kichul Shin,Hyun Mi Kwon,Min Jung Kim,Myung Jae Yoon,Hyun Gyung Chai,Seong-Wook Kang,Won Park,Sung-Hwan Park,Chang-Hee Suh,Hyun Ah Kim,Seung-Geun Lee,Choong Ki Lee,배상철,Yong-Beom Park,Yeong Wook Song 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.5
Background/Aims: The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued. Methods: Sixty Korean patients with RA who participated in a 5-year GO-BEFORE and GO-FORWARD extension trials were included in this retrospective study. Golimumab was deliberately discontinued after the extension study (baseline). Patients were then followed by their rheumatologists. We reviewed their medical records for 2 years (max 28 months) following golimumab discontinuation. Patients were divided into a maintained benefit (MB) group and a loss-of-benefit (LB) group based on treatment pattern after golimumab discontinuation. The LB group included patients whose conventional disease-modifying antirheumatic drug(s) were stepped-up or added/switched (SC) and those who restarted biologic therapy (RB). Results: The mean age of patients at baseline was 56.5 years and 55 (91.7%) were females. At the end of follow-up, 23 (38.3%) patients remained in the MB group. In the LB group, 75.7% and 24.3% were assigned into SC and RB subgroups, respectively. Fifty percent of patients lost MB after 23.3 months. Demographics and clinical variables at baseline were comparable between MB and LB groups except for age, C-reactive protein level, and corticosteroid use. Restarting biologic therapy was associated with swollen joint count (adjusted hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.01 to 3.55) and disease duration (adjusted HR, 1.12; 95% CI, 1.02 to 1.23) at baseline. Conclusions: Treatment strategies after discontinuing TNF-αi are needed to better maintain disease control and quality of life of patients with RA.
( Kichul Shin ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Human epidermal growth factor receptor 2(HER2) positive breast cancer patients are at increased risk for disease progression and death compared to those who do not. We report a case that complete remission of HER2+ breast cancer with pulmonary and pancreatic metastases. A 37-year-old female was diagnosed with invasive ductal carcinoma of the right breast. She underwent a total mastectomy and axillary lymph node dissection in May 2003. The immunohistochemistry of the tumor was hormone receptor negative and HER2 positive. She received adjuvant chemotherapy(cyclophosphamide, methotrexate and 5-FU) but in January 2007, a pulmonary nodule was detected. So lobectomy of right lower lobe was performed. Paclitaxel plus trastuzumab were given and administered consecutive 35 cycles of trastuzumab until progression. In March 2009, the pancreatic lesion was detected. Pylorus preserving pancreaticoduodenctomy was done and metastatic infiltrating ductal carcinoma was confirmed. and she received combination chemotherapy with doxorubicin and cyclophosphamide, and gemcitabine and navelbine. But lesion of pancreatic tail was newly detected in May 2010. She received image-guided radiation therapy to pancreatic tail. Lapatinib plus capecitabine was started in July 2010. The pancreatic tail mass is on complete remission for 40 months from May 2011. A phase III, randomized, open-label study showed that lapatinib plus capecitabine is an active combination in women with HER2 positive metastatic breast cancer previously exposed to anthracyclines, taxanes, and trastuzumab. Our patient was also resistant to chemotherapies such as anthracyclines, taxanes, and trastuzumab. But she have sustained complete remission status for 40 months, since lapatinib plus capecitabine chemotherapy started. Lapatinib plus capecitabine chemotherapy is considered as an effective therapeutic option of trastuzumab resistant metastatic breast cancer.
( Kichul Shin ),( Sung Soo Kim ),( Sang-heon Lee ),( Seung-jae Hong ),( Sung Jae Choi ),( Jung-yoon Choe ),( Seung-geun Lee ),( Hoon-suk Cha ),( Eun Young Lee ),( Sung-hwan Park ),( Jin-wuk Hur ),( Su 대한내과학회 2020 The Korean Journal of Internal Medicine Vol.35 No.1
Background/Aims: The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA) in daily clinical practice. Methods: This was a nationwide multicenter observational study. Patients who had three or more active joint counts and abnormal inf lammatory marker in blood test were enrolled. The selection of DMARDs was determined by the attending rheumatologist. Clinical parameters, laboratory findings, and Health Assessment Questionnaire (HAQ) scores were obtained at baseline and at 6 and 12 months. Serial SDAI changes and clinical remission rate at 6 and 12 months were assessed. Results: A total of 850 patients participated in this study. The mean baseline SDAI score in bDMARD group was higher than that in cDMARD group (32.08 ± 12.98 vs 25.69 ± 10.97, p < 0.0001). Mean change of SDAI at 12 months was -19.0 in the bDMARD group and -12.6 in the cDMARD group (p < 0.0001). Clinical remission rates at 12 months in bDMARD and cDMARD groups were 15.4% and 14.6%, respectively. Patient global assessment and HAQ at 12 months were also significantly improved in both groups. Multivariate logistic regression showed that baseline HAQ score was the most notable factor associated with remission. Conclusions: There was a significant reduction in SDAI within 12 months after receiving DMARDs in Korean seropositive RA patients irrespective of bDMARD or cDMARD use in real-world practice. Clinical remission was achieved in those with lower baseline HAQ scores.
Kichul Shin,Jinsu Kim,Seokyoung Yoon,Eung-Ho Cho,Changwon Jung,Hye Jin Kang 이화여자대학교 의과학연구소 2015 EMJ (Ewha medical journal) Vol.38 No.3
A 37-year-old woman underwent a total mastectomy and adjuvant chemotherapy for HER2-positive breast cancer (pT1N0M), and then recurred in the right lung followed by the pancreas. Lung lobectomy and pylorus-preserving pancreaticoduodenectomy were performed, and systemic chemotherapies including trastuzumab were sequentially administered. However, metastasis to the pancreatic tail was detected. She underwent image-guided radiation therapy, but this was not effective. Lapatinib plus capecitabine combination was administered as forth-line treatment and the metastatic lesion was disappeared. She is continuing this regimen with a complete response for 48 months until now.
신기철(Kichul Shin),박태수(Taesoo Park),박상철(Sang. C Park),왕지남(Gi. N Wang) (사)한국CDE학회 2011 한국 CAD/CAM 학회 학술발표회 논문집 Vol.2011 No.1
As we move into the late 20th century the manufacturing system has been developed continuously with automatic system. In this process, PLC (programmable Logical Controller) program has also improved the proportion of process control. However, sometimes an error can be occured the obsolete equipment or PLC due to makes the signal in put / output in the process. Because of this, if an accident occurs between facilities the accident can cause a serious problem of the production process and personal injury. At present, PLC simulation is using a direct modifying way , that fix the problem after checking a problem through a test operation in the field, because it is giving a importance to check sequence, however this way has to waste much time and manpower. Therefore, the verification technology that check a sequence or a problem is needed in the PLC simulation of the future facility process for the loss reduction and the improvement of the program quality. The objective of this research is which propose the improvement way of PLC program. If the process system use a simulation modelling a problems of process based on actual cases in the field, the simulation result can use for checking the sequence or safety circuit before actual operating process, and also it can improve of PLC program quality.
신기철(Shin Kichul),이승훈(Lee Seunghoon),권재영(Kwon Jaeyoung),장현국(Jang Hyunkook),이희연(Lee Heeyoun) 한국HCI학회 2019 한국HCI학회 학술대회 Vol.2019 No.2
이번 연구는 영상인식과 립모션을 활용하여 농인들의 언어인 수어를 한국어로 번역하여 출력하였습니다. 영상인식을 활용함으로써 사용자의 접근성을 높였고, 립모션을 사용하여 손동작 인식의 정확도를 높였습니다. 뿐만 아니라 기존의 한국어 형태소만을 번역하는 원론적인 번역이 아닌 실제로 농인들의 일상생활에서 자주 쓰이는 수화동작들을 추출하여 번역함으로써 실제 생활에서 사용할 수 있는 실용적인 번역 시스템을 구축하였습니다.
부분기여도함수를 이용한 GDI 제품의 진동기여도 분석기법 연구
신기철(Kichul Shin),이상직(Sangjik Lee),윤준석(Junseok Yoon),이상권(Sangkwon Lee) 한국자동차공학회 2012 한국자동차공학회 부문종합 학술대회 Vol.2012 No.5
This paper presents the method estimating the contribution of vibration sources in GDI powertrain components with a multiple input system. Partial coherence function (PCF) has used to identify the cause of a linear dependence indicated by an ordinary coherence function. In order to apply the PCF to the vibration source identification in power train system of a GDI gasoline engine, the virtual model of two inputs and single output system is simulated. For the validation of this model, the vibration of powertrain components was measured by using tri-axial accelerometers attached on the selected vibration sources, which are high pressure pump, fuel rail, injector and pressure sensor. After calculating the partial coherence between each source based on the virtual model, the vibration contribution of powertrain system is calculated. This virtual model based on PCF is implemented to determine the quantitative vibration contribution of each powertrain components.
( Ha Shin Kim ),( Hae Sun Jeon ),( Soo Jin Han ),( Ji Hoi Kim ),( Jae Hoon Chang ),( Yun Kyu Oh ),( Kichul Shin ),( Byoung Jae Kim ),( Seung Mi Lee ) 대한주산의학회 2019 Perinatology Vol.30 No.1
Diffuse alveolar hemorrhage (DAH) is a rare and life-threatening complication of systemic lupus erythematosus. Differential diagnosis and successful management of DAH can be problematic in pregnancy. We report a case of a 35-year-old pregnant woman who was presumptively diagnosed with DAH and treated during the antepartum period, resulting in symptomatic improvement and successful delivery after immunosuppressive treatment.
신기철(Kichul Shin),서상기(Sangki Seo),왕지남(G. N Wang),홍상현(SangHyun Hong),남중호(Joongho Nam) 대한산업공학회 2011 대한산업공학회 추계학술대회논문집 Vol.2011 No.11
생산의 최적화를 위해서 제조업에서는 자동화 설비를 구축하고 사용하고 있다. 사용되고 있다. 이러한 자동화 설비들은 PLC(Programmable Logical Controller)에 의해서 제어되고 있다. PLC의 신호입, 출력을 통해서 공정을 제어하고 이상 상황에 대해서 반응하여 움직인다. 공정의 운용이 새로운 제품에 따라서 1년에도 여러 번 변경이 되고 있다. 이에 따라서 PLC가 새로이 작성되는 상황에서 공정의 시퀀스를 체크하는 시뮬레이션이 많이 사용되고 있다. 하지만 PLC에서도 상당부분을 차지하고 있는 이상 및 안전 회로의 검증은 시운전 시에 간단하게 확인을 하는 차원에서 이루어지고 있다. 본 논문에서는 실제 시뮬레이션을 통한 이상 회로의 검증을 실시하게 되는 경우 이상 회로의 여러 형태에 따른 이상 회로를 분류하여 형태별 이상 회로 검증을 제안하고자 한다. 제안하는 분류 방법은 실제 자동차산업의 사례를 바탕으로 PLC에 다양한 형태로 정의 되어 있는 이상회로를 명확한 형태적 분류와 기능적인 분류를 통해 이상 회로에 대한 효과적인 검증을 실시하기 위한 기본적인 틀을 마련하여 PLC프로그램의 효과적인 검증 방법의 제시하고자 한다